Business / Finance

RSS

Pall first quarter 2013 sales decrease 3.6% to $627.6 million

Pall Corporation today reported financial results for the first quarter of fiscal year 2013 which ended on October 31, 2012.

From Pall Corporation 29 Nov 2012

Rexahn intends to offer shares of common stock and warrants

Rexahn Pharmaceuticals, Inc. today announced that it intends to offer shares of its common stock and warrants to purchase common stock in an underwritten public offering.

29 Nov 2012

Ginger.io announces $6.5M Series A funding

Ginger.io, the behavioral health analytics startup, today announced a $6.5 million Series A funding round led by Khosla Ventures.

29 Nov 2012

Pfizer completes acquisition of NextWave Pharmaceuticals

Pfizer Inc. today announced that it has completed its acquisition of NextWave Pharmaceuticals, Inc., a privately held, specialty pharmaceutical company focused on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD).

29 Nov 2012

Kewaunee Scientific second quarter sales increase 20% to $31,185,000

Kewaunee Scientific Corporation today reported sales and earnings for its second quarter ended October 31, 2012.

28 Nov 2012

Merck increases quarterly dividend to $0.43 per share of common stock

Merck, known as MSD outside the United States and Canada, today announced that the Board of Directors has increased the company's quarterly dividend to $0.43 per outstanding share of the company's common stock, up $0.01 from $0.42 per outstanding share paid last quarter.

28 Nov 2012

Sonomax third quarter net revenue increases to $267,946

Sonomax Technologies Inc. today disclosed its results for the three-month and nine-month periods ended September 30, 2012.

28 Nov 2012

Big pharma and federal government predicted to play diminishing role in research funding

In a commentary to be published in the Dec. 12 issue of The Journal of the American Medical Association, two Johns Hopkins faculty members predict an ever-diminishing role for government and drug company funding of basic biomedical research and suggest scientists look to “innovative” kinds of private investment for future resources.

27 Nov 2012

TriReme raises new financing round

TriReme Medical, Inc. and its affiliates announced today a new round of financing that brings a total of US$18 million into the group.

27 Nov 2012

Rhythm raises additional $8 million to complete Series B financing

Rhythm announced today that the company has raised an additional $8 million to complete a $33 million Series B financing.

27 Nov 2012

Mazor Robotics third quarter revenue increases 171% to $4.2/16.2 million NIS

Mazor Robotics Ltd., a developer of innovative surgical robots and complementary products, today filed its financial statements with the Tel Aviv Stock Exchange for the third quarter ended September 30, 2012.

27 Nov 2012

TransMedics closes $36 million financing round

TransMedics, Inc., the global leader in organ preservation technology, announced the closing of a $36 million financing round led by Abrams Capital with the participation of existing investors including Flagship Ventures, Hercules Technology Growth Capital and Kleiner Perkins Caufield & Byers.

27 Nov 2012

Aware declares special cash dividend of $1.80 per share

Aware, Inc., a leading supplier of biometrics software and DSL service assurance products, previously announced on November 19, 2012 that its Board of Directors had declared a special cash dividend of $1.80 per share, or approximately $40 million in total.

27 Nov 2012

Patheon announces cash tender offer for all outstanding 8.625% Senior Secured Notes

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that it is commencing a cash tender offer for any and all of its outstanding 8.625% Senior Secured Notes due 2017 (CUSIP Numbers 70319W AA6 (Rule 144A) and C7197E AA2 (Regulation S)), upon the terms and subject to the conditions set forth in the Offer to Purchase, dated the date hereof, and in the related Letter of Transmittal.

27 Nov 2012

Weight Watchers declares quarterly cash dividend of $0.175 per share of common stock

Weight Watchers International, Inc. today announced that its Board of Directors declared a regular quarterly cash dividend of $0.175 per share of common stock, which corresponds to an annual dividend rate of $0.70 per share.

27 Nov 2012

XTL Biopharmaceuticals purchases 4,620,356 shares of Proteologics from Teva

XTL Biopharmaceuticals Ltd., a biopharmaceutical development company, announced on November 21st that it has acquired 4,620,356 shares, of Proteologics Ltd., from Teva Pharmaceutical Industries Ltd. in consideration for an amount of approximately NIS 6.5 million, which represents an amount of NIS 1.405 per Share (approximately 22% premium).

27 Nov 2012

Hillenbrand fourth quarter net income increases 6% to $25 million

Hillenbrand revenue for the fourth quarter of 2012 grew 10% to $254 million compared to the same quarter last year. This represents 11% revenue growth on a constant currency basis.

26 Nov 2012

Viral Genetics changes name to VG Life Sciences

Viral Genetics, Inc. today announced that it has changed its name to VG Life Sciences Inc. and that it has completed its 1-for-600 reverse stock split, both of which will take effect at the open of trading on November 27, 2012.

26 Nov 2012

Renal care provider Diaverum signs contract with Bureau Veritas to standardise ISO certifications

Diaverum, one of the world's leading renal care providers, has signed a contract with Bureau Veritas (BV) to standardise ISO certifications within the company. A pilot project has successfully been rolled out in Hungary and Poland earlier this year. In 2013 the ISO certification project will be expanded to an additional five countries in Diaverum.

26 Nov 2012

Ivoclar Vivadent announces acquisition of Wieland Dental

Ivoclar Vivadent, headquartered in Schaan, Liechtenstein, announced the acquisition of Wieland Dental today. The acquisition is planned to be completed in the fourth quarter of 2012. The transaction is still subject to approval by the German Federal Cartel Office.

26 Nov 2012